Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 43%
Buy 52%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health, a prominent player in liquid-based cancer diagnostics, is experiencing robust growth with a two-year revenue compound annual growth rate (CAGR) projected at +28% from 2023 to 2025, driven by the successful introduction of products like Shield and ongoing strength in colorectal cancer (CRC) and breast cancer applications. The company has also raised its annual revenue guidance for 2025, anticipating approximately 31% year-over-year growth, reflecting positive market demand and expansion into new monitoring applications. Additionally, Guardant's shares have demonstrated significant momentum, increasing by 136% year-to-date, which, along with its enhanced long-term revenue growth and margin assumptions, positions the company favorably in the market, potentially attracting larger institutional investments.

Bears say

Guardant Health's medium-term revenue guidance for its new Shield product has been perceived as underwhelming, contributing to a negative outlook for the company. The company reported an adjusted EBITDA loss of $45.5 million in Q3 2025, highlighting ongoing financial challenges. Additionally, potential setbacks related to regulatory approvals, reimbursement issues, and the timing of new product launches raise concerns about future growth and profitability.

GH has been analyzed by 21 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 52% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 21 analysts, GH has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.